Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 9/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121753 | 0.87 | MAP2K1 (0.44) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL30033040 | 0.85 | MAP2K1 (0.51) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL949843 | 0.85 | MAP2K1 (0.44) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL949141 | 0.85 | MAP2K1 (0.51) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL3120057 | 0.84 | MAP2K1 (0.46) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL4107958 | 0.84 | MAP2K1 (0.52) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL30034530 | 0.82 | MAP2K1 (0.57) | MAP2K1MAP2K2 | |
| SCHEMBL20565262 | 0.82 | MAP2K1 (0.57) | MAP2K1MAP2K2 | |
| SCHEMBL4109917 | 0.82 | MAP2K1 (0.45) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL4127886 | 0.82 | MAP2K1 (0.44) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2013-06-13 | — | — | US | claimed |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2012-12-27 | — | — | US | claimed |
| US-8283359-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2012-10-09 | — | — | US | claimed |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | US | claimed |
| US-8604051-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2013-12-10 | — | — | US | disclosed |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2013-06-13 | — | — | US | disclosed |
| US-8394822-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2012-12-27 | — | — | US | disclosed |
| US-8283359-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2012-10-09 | — | — | US | disclosed |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | MAP2K1 25/4885MAP2K2 11/4885HDAC3 1752/4885 |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | MAP2K1 25/4885MAP2K2 11/4885HDAC3 1752/4885 |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAPK1, MAP3K6 | MAP2K1 4/4885MAP2K2 1/4885HDAC3 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.